<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-053590
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20061220
<FILING-DATE>20061220
<DATE-OF-FILING-DATE-CHANGE>20061220
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>061288932
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v060891_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
      D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of December 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number 000-5112</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Level
      12 BGC Centre</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>28
      The Esplanade</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Perth
      WA 6000</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Australia</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
      incorporated by reference herein and into the following registration statements:
      (i) the Registrant's Registration Statement on Form&#160;F-3, Registration
      No.&#160;333-132776; (ii) the Registrant's Registration Statement on
      Form&#160;F-3, Registration No.&#160;333-132777; and (iii) the Registrant's
      Registration Statement on Form&#160;F-3, Registration
      No.&#160;333-135428.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
      20, 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSIVIDA
                LIMITED</strong></font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/Michael
              J. Soja</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Michael
              J. Soja</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
              President, Finance and Chief Financial
              Officer</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div>&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Press
                Release: pSivida completes US$2.9m placement; Dr. Roger Aston reappointed
                to the pSivida Board</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v060891_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      completes US$2.9m placement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dr
      Roger Aston reappointed to the pSivida Board</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia (December 20, 2006) - Global bio-nanotech company
      pSivida Limited (NASDAQ:PSDV, ASX:PSD,Xetra:PSI) today announced the placement
      of 14,230,768 million fully paid ordinary shares to Australian and European
      investors issued at AU$0.26 (US$2.00 ADR equivalent) each to raise US$2.9m
      before costs. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      share was purchased with two free attaching options at an exercise price of
      AU$0.26 and a term of four years. This raising is an interim financing measure
      prior to the expected closing of the definitive documents with Nordic Biotech
      Advisors for a US$4.0m corporate investment in pSivida and a US$22.0m investment
      over time in a &#8220;Special Purpose Vehicle&#8221; (SPV). The SPV is expected to fully
      fund pSivida&#8217;s portion of costs to develop its lead ophthalmic development
      product, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for the
      delivery of a steroid (fluocinolone acetonide) for the treatment of the chronic
      eye disease diabetic macular edema (DME). The Company is committed to reducing
      its cash burn with cost cutting measures to begin at the end of this
      month.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is also announced the reappointment of Dr. Roger Aston to the pSivida Board
      of
      Directors. Dr. Aston is a founding director of the Company and returns to the
      Board following his departure in November 2005. Dr. Aston has more than twenty
      years&#8217; experience in the pharmaceutical and biotechnology industries and is a
      welcome addition to the Board. Dr. Aston is also a director of Clinuvel Limited
      and Halcygen Limited.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;This
      capital raising places the Company in a stronger financial position with
      opportunities to accelerate R&amp;D commercial activities, particularly in the
      area of controlled slow release drug delivery technologies,&#8221; said Dr. Roger
      Brimblecombe, Executive Chairman and CEO of pSivida Limited. &#8220;I am particularly
      pleased by the reappointment of Dr. Aston to the pSivida Board as we move toward
      significant commercial opportunities in the near term.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      required by NASDAQ regulatory rules, pSivida also announced that its independent
      registered public accounting firm's report on its financial statements for
      the
      fiscal year ended June 30, 2006 includes an explanatory paragraph regarding
      the
      Company's ability to continue as a going concern. The independent auditor&#8217;s
      opinion noted that the Company has suffered recurring losses from operations,
      has had significant recurring negative cash flows from operations and has
      determined that there may be a risk of default associated with a loan covenant
      that requires the company to maintain a minimum net cash balance and those
      raise
      substantial doubt about its ability to continue as a going concern.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      the
      independent registered public accounting firm's report appeared in the 2006
      Annual Report, the Company is taking steps to reduce the cash burn and
      successfully raised additional capital as detailed above as well as entered
      into
      a significant capital raising initiative with Nordic Biotech
      Advisors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
      by:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Director
                of Investor Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Tel:
                (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>European
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Accent
                Marketing Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Eva
                Reuter</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Tel:
                +49 (254) 393 0740</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">e.reuter@e-reuter-ir.com</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">pSivida
      is
      a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482; for diabetic
      macular edema is licensed to Alimera Sciences and is in Phase III clinical
      trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialize a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 76 patent families, 95 granted
      patents, including patents accepted for issuance, and over 300 patent
      applications. pSivida conducts its operations from offices and facilities near
      Boston in the United States, Malvern in the United Kingdom, Perth in Australia
      and Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">pSivida
      is
      listed on NASDAQ (<strong>PSDV</strong>), the Australian Stock Exchange
      (<strong>PSD</strong>) and on the Frankfurt Stock Exchange on the XETRA system
      (<strong>German</strong>&#160;<strong>Symbol: PSI. Securities Code (WKN)
      358705</strong>). pSivida is a founding member of the NASDAQ Health Care Index
      and the Merrill Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties including with respect to the potential signing of definitive
      agreements with Nordic on the terms described; the amount of pSivida&#8217;s portion
      of the costs to develop Medidur&#8482; for DME; the potential size of certain markets;
      and potential products, applications and regulatory approvals. Although we
      believe that the expectations reflected in such forward-looking statements
      are
      reasonable at this time, we can give no assurance that such expectations will
      prove to be correct. Given these uncertainties, readers are cautioned not to
      place undue reliance on such forward-looking statements. Actual results could
      differ materially from those anticipated in these forward-looking statements
      due
      to many important factors including: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">Failure
      of
      the company to successfully close the transaction with Nordic contemplated
      by
      the MOUs with Nordic; the failure of the Company to obtain the requisite
      shareholder approvals to complete the Nordic transactions; failure of pSivida&#8217;s
      share of Medidur&#8482; development costs to be no more than US$22m; failure of the
      results of the Retisert&#8482; for DME trial to be a good indicator of the results of
      pSivida&#8217;s ongoing Phase&#160;III Medidur&#8482; for DME trial; failure of the Medidur&#8482;
trials in DME to show a very similar improvement in visual acuity and diabetic
      retinopathy severity score as Retisert&#8482; for DME; failure of Medidur&#8482; to release
      fluocinolone acetonide at the same rate as Retisert&#8482;; our inability to recruit
      patients for the Phase&#160;III Medidur&#8482; for DME trial; our inability to raise
      additional funds at favourable terms or any terms; our inability to repay the
      amended notes and new convertible notes; our inability to develop proposed
      products, including without limitation, in the drug delivery, wound healing,
      orthopaedics, and tissue engineering, diagnostics and food technology fields;
      failure of our evaluation agreements to produce favorable results and/or result
      in license agreements; failure to develop applications for BioSilicon&#8482; due to
      regulatory, scientific or other issues; failure to complete negotiations for
      new
      centers for the BrachySil&#8482; Phase&#160;IIb clinical trial for inoperable primary
      liver cancer; failure of our discussions with the FDA for BrachySil&#8482; to continue
      or to lead to FDA approval; failure of the BrachySil&#8482; Phase&#160;IIb clinical
      trial for inoperable primary liver cancer to determine the optimal dose, provide
      key safety data or support future pivotal efficacy trials or product
      registration or approval; failure of the BrachySil&#8482;&#160;primary liver program
      that is in Phase&#160;IIb clinical trials to&#160;provide a valuable platform
      for the development and commercialisation of BrachySil&#8482; for pancreatic cancer
      and other indications; failure of the findings&#160;of the pancreatic cancer
      Phase&#160;IIa trial to provide a platform for further multicenter efficacy and
      safety trials; and failure of there to be optimisation&#160;and standardisation
      between our two&#160; pancreatic cancer&#160;study&#160;centres. Other reasons
      are contained in cautionary statements in the Annual Report on Form 20-F filed
      with the U.S. Securities and Exchange Commission, including, without limitation,
      under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral
      or written forward-looking statements that may be made by or on behalf of
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````6@``_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0(!`0$"`@(!`0("`@("`@("`@,"
M`P,#`P(#`P0$!`0$`P4%!04%!0<'!P<'"`@("`@("`@("`$!`0$"`@(%`P,%
M!P4$!0<("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(
M"`@("`@("`@(_\``$0@`0P#A`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0(%`@,$!@8%!0$#!F\!`@,$$04&(1(`!S%!$PA1(F$4<8$RD0FA(_#!
M0K$5T1;A\5(S%R1B&$,T)8(*&7)3)F.21#6B5+(:<S;"TB=%-T;B\H.3H[-D
M52C#TRDXX_-'2%9E*CDZ24I76%E:9G1UA(5G=G=HAH>4E:2EM+7$Q=35Y.7T
M]9:7IJ>VM\;'UM?FY_;W:6IX>7J(B8J8F9JHJ:JXN;K(R<K8V=KHZ>KX^?H1
M``$#`@,$!P8#!`,&!P<!:0$"`Q$`!"$%$C$&0?!180<3(G&!D:&QP0@RT13A
M(_%"%5()%C-BTG(D@L*2DT,7<X.BLF,E-%/BLS4F1%1D154G"H2T&!D:*"DJ
M-C<X.3I&1TA)2E976%E:969G:&EJ='5V=WAY>H6&AXB)BI25EI>8F9JCI*6F
MIZBIJK6VM[BYNL/$Q<;'R,G*T]35UM?8V=KCY.7FY^CIZO+S]/7V]_CY^O_:
M``P#`0`"$0,1`#\`W^.>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU5F>H7\4+HY
MTNS_`"=`^AV5L8]7GJ@D#+'T2R(D=:V',%^WC&),?E*")2??,CEAXK?BUJR4
M1*L!UU&^?=I=I;/_`):V2;BX_H(QC_&5L'7T<:!NHR)^-1UPPA\R8GUPZ7^C
M)9D:;".F^$8!4YVQ&&Z[TBQ'$\0=(;BX#^1'WO;CP7;(.PJHE58[Y7J"M3K5
MMT)`U'U)D>RA,_",]7G63UC^F/&\Z==,+H$S[D#-F.93K\VX5`U-AN8!@SQI
M\[#"2P0DN5<*=MQ<`7MQK,+=+:X31GV4;VW>;Y<7+D#6A93(V*@`S[XJTOB&
MI/KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW
M/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZNB0`2=`.YYHD`2:]0<8-UAZ6Y@Q%L
M(P;/N%UV)HYC-"M7$LAD#;2H#D7-Q:PY#.[OU$[BYM>&UM,QMUO@QIU@&9B`
M#$F>`HQ>RFY;3J4@@>5"'//!2PRU%3,E/3PJ6FG=@B(HU)9FL`!R7[JZ:8;+
MCB@E"1))(``Z23@!1>E))@4P?URR?_V%>&_^-U+_`,U\"/\`LE[N?\SMO_JK
M?^%2C\F]_1/L--F-=0LKX5A&)XG2XK38[4X?!+-3X+1UE&]55O&A=8H5>55+
MN19;D"_<\LGM)W<)C\[;CS=;_P`*F;AA]""H(4H@;`,3U"J@LT]//Q'/Q!LP
MXQESJ+7U7X>7I$IIWIJW*^"8E1XGU/SM2:AA-B-"SP8932J;$1,S$']X<D-F
MXMDH"VR')$@C%,'80>(J%;K+MXL^<*'ILK784@@N*Z02,$CG&CO>GGI9Z*O1
MAEVEZ2=#J3+O3\UTL:XH\=2E5C.,5SL(_-Q"MD,D]1.[>,CFQT``TY"&>?4E
MN1;9@FRN,RMQ<*4$A&L$ZB8`\,P9P@\:E7=?L]9RNVT6C.E/$QB>LDXF@U_$
M8Z^]0LGY%R_Z9_3=",:]6_JI-7@/2FAC?:,O868]F+9FKF57,-)AT#DB0@7E
M**MSIR;;-H$ZE?:*!G:'GK[3`L[3&[N)2G^]'\2ST`#CTT8ST@^F;)_H_P#3
MKTQ]/F29378;D&@6+$\=D14GQ7%)V-16UTH7]^>=V?QL"!?3C-R^7%E1H0;H
M;LLY1ES=JWB$#$]).)/J:,IQBA+7N>KU>YZO5[GJ]7N>KU>YZO4V5V-8/A;I
M'B6+4V'22@M''//%"S*#:X$C"XX29KO-EMBH)N7FVB1("UI22.D213B&5JV`
MFI\,T-1%'/3RK/!*`T4R,&1E.H(*W!!X:V]PV\V%MD*2H2"#((Z01MJA!!@U
MDX]6J]SU>IEQ_,F7<J8<^,9HQZBRWA$3(DF*5]5!1TRO(=JJ9:AD4%CH!?7F
MTI)V4Q<W33*=3B@E/23`]]1\MYOREG&EGK<H9HP[-5%2R>54U>&UM-711R[0
MVQGI7<!K$&Q-^;4@C;A5;6]9?$MJ"@.@@_"E%RM*:]SU>KW/5ZO<]7J]SU>K
MW/5ZO<]7J]SU>KW?3FB)KU$$]3'23!)#!!E?+1PQI:>6M0X1EN">1JV&0N#)
M7121/$'OJ+'V\Y+?6YV`Y:J$97:EDEM3H_+V:%$N))/B?"DJ0%<1!&&JAWNW
MFB]JU3C&*N'E0A>F+.+=8NCV*98SP#C53@KR83C?FLQ>JHY(@T9D8$$MM)0F
M]S:_)?\`H;[25=H_9R]EN=?MUVY-N[J)EQM2925&9F)23,G3.TT7[RV?Y.["
MV\`<1U&B=^K?I;D?IEFG*M)DK!_Y-28Q0RRUE&)994\R*?RPR^<S%=#J`;<Y
MM_UB?8;NUN1GUFWDS/<-OM*4I.I2AJ"H!&HDC#:`8H8;I9D]<M*+AD@TX^D3
MI+D'J?B.=_Z\8&,;BP2*C_E],TTT4:FH:7>2(66Y]P6N=.'O]7+V!;K;[WE^
MK.F._%NEO0-2D@%97).DB3X1$F!36]V:/VR4=V8F9HTOJTSY6=-NFF`9*R;(
MV%UN9V7#J-H6(D@PZEB5'2-NX+`J@-[VOS._^L&[5KC<K<FVR;)R67+LAE.D
MG4EE"0"E)V@F4IF9B>.-!C=6Q%S<EQS$)Q]324]/?2S"<)PS%9L4R>V8:[`X
M(JG#*3$\N4M!5MB,C&;]'6RR2M)9AM!(`4:\#'T2]@&5,(4+^U[TLA"P;BR0
MVL.*.HE+Q4M3FF(`,0((IS>C-W(E!VS@%;>J-@FA6Z+>GJGR3GG/77;J!61Y
MPZ^]44BI<P9K*DPX-@-+(TM'@.%+(6,-%`6+O;6:4M(^NT+U2>?D!(P2.9J(
MLBW<[A]=T\==PYM/!*1L0GH2/><31G.)Z%5>YZO5[GJ]7N>KU50=>_4'U!SM
MU`Q#(60<3J<*P*@K/Y;04E`S1U6)58?RF9Y$LVTOHJ@@>)Y\_P#]6WU?[X;S
M;W.9#D#KC-JV[W*4M$I6\L'225"%058)2"!&)DU*>0Y!;LVX==`*B)QV`4AL
MTY4]2G12GP_-V,XQB6%4DTBJN(P8HU9'%*PNJ3J'=1N[686/;D5[^[@]MO9>
MRUFUV^^TV5`:TOEQ*5'8EP!2@)V0H%)V8TNM;K+;TEM(!/E'LJPOTU];&ZR9
M/J),66.+-N6Y$I\P)$`L<V]=T<Z*/LAP#=?`@^'.Q'T4_4VOM(W;4N[`3F%L
M0ET#`*D>%P#AJ@@C8%`QA%1_O'DPLWH3]AV?A2,]27IQS'ULQ_+F+X+F"BP>
M'!J*:EFBJ4G9G>2;S`P\K2UN1U]9_P!&^<]IF;6MW97+3"6&B@A85))452-(
M.%+-W=X6[-M25`F3.%&3R'EZHRGDO*V6:NH2JJ<!H::EGJ8PP1VAC"%E#:V-
MO'F:'91N>]N_NS9Y:ZH+7;,H;*A,$I`!(G&#UT';ZX#KREC83-*WD@TDKW/5
MZJ]/Q/\`T=9Q]=GI-S%Z?,BYLPW)>8,9QC!,2AQW%8ZJ6C2/"ZP5+H5I`7W,
M!8?GQ98W(:<U&H][3MSWL]RHVK2@A14DR=F'E02_A%_A[]0?P[>C?4SIKU#S
MWA&?L2SQF48W0XC@\5;%!#`,-IZ+RW%:`V[="3II8\>S*]2^H$"(HG[(NSVX
MW=LW&7EA96K5(GH`XU;+PMJ6JIP_'>Z@9\Z9?AWYYS9TXSGBF0LTTN8LJ14V
M8\'K9\/K8XI\72.1%FIF5PKJ;,+ZCAKDS84^`:A?M\S.XM-W%NLJ*%A2<02#
MMZJ+;_PG*ZK]4>K7IJZZXQU4ZCXWU)Q;#<[BGP[$\<Q*JQ.>GI_Y/3R>5&]4
M[E4W$FP-K\?SUI*'``(H-?39G-W>Y6ZM]:ED+&TD_P`(Z:V(>$=9&U[GJ]7N
M>KU>YZO5[GJ]7N>KU%9]1V$T%5/E6MJ\,H:]BM5`CU6#XUBLBW"N`O\`*)$V
M#_B8U/;F"?UE9':O.VCSK3+A(6@=Y;W+Y&PP/RZAI'^-M.RA-N\ZH!0!(V;"
M!\:K?H^NW5[T\]%.M6(]!NCE9UMZW8[C>`X'T]Z>P(\<4&(8M/44,5=7JQ#Q
MT5,Y#3'0@6!(%R,:OZJ"X0W?9U8.'0M*FUZ2"DPE3B3X58B)&!Q&PXT6]M><
M7=E8-NVS9==4="0,0"K83'#W=)`QI,XWTIZY]'NEO23+GJ6ZI'K#USQ[^?Y@
MZB9N0%:2"LQK$A5_RZC!M:EHP?*BL`+#0`<C;^MV>0O>3+-(@"W6/_0E+>Q'
M*KVSRM2;M?>/*65*/03P'4/0=``HY'H&_P![^IO_`"ZPS_E:?A[_`%1__%.;
M?XK'Q<H2[^;&_7Y5S];,@Q#J!TGP.$?-3B.:26B$<DY*2U4:"\4'OL#L/NKJ
M?#BC^L\>3>;W9-9)\:]*B4Z5+P4XD8H3XC.DX#$@857<P:6'%<[*,7Z<\,P^
MFH\U5M!AU%0K-40Q.:/"L8PK=LC+#<F+R.S6W:%;#V\S1^CK)[5JWO'F6VFP
M5I3^S8N&)@$XBX4HJ&.!3@-AH.[P.*)2"2?,@_"C+<S4H.U[GJ]6AEZRO5KZ
MN^G'XP'5+`.D?5/,6.O@?4?#Z3I[TAJ<>KH<N5=94T=)#34<U.)4C%.TTH+K
MH#K?@RM;1I5J"KHK`/?7?7.+7?-QJW6HPX`E))B<($3$5(_$O],GXI/I4PS)
M'JQZ_>K;$<[8GGG%5IL4GROC^-4,64\6J8VJX*6.!1!!Y'N-'&T2[05L18@F
MN7/6[I*`(I[M3W<WKRA",PN+@J*CCI4KPG;'`1MV885LZ_@W^K?.OK&]#^2>
MH'4[$1C74W)F(8AE;/./[51\2JL)\MH:R0(`!)-3SQ-)8"[W/CP@S6U#3Q`V
M5D_V,;XO9WD2'GC+B24J/3$03UP1/70+=2,!S5T0ZUU>)R4NVIH<5?%LL5TJ
M$TU9"\YG6Q\;7VN!J#SY:>VW=7/^RWM/7=J1XF[@OLJ4)0XDKU@SQVZ5#:#(
MK,#+7VKVRT](@]56#9(]0'2#KU@CY+S?3185B>+JD=?E3$6`@JG5@X\B8$!_
M>`(%PWPYV![+/J^[.NUC+/Y/FJ4LOO`!3#Q\*R"#^S7@#B)`\*^J@!?9!=V*
M^\1B!Q'S%&0RYE#*V4*8T>5\OTF`TS@"2.E@CAW;>VXJ`3;X\S2W-[/,BW=8
M[G++9JV08D-I"9C9,"3ZT';B[==,K))ZZK^];V;<UY<S?DN#+V9:[`X*G"ZA
MZB&DJ98%=Q4D!F$9%S;G(S^M`[1<^R7>*P1873K"5L*)"%J2">\(D@$28H>;
MEVC3C*RI(./$=5/_`*H\GY]ZI_AR]2\(R-FS%\O]3),AR8IE3-&%UM32XJ,5
MPNC&*1>7/3L'W2M!Y9%]=UN=3?IMS)ZYW+RQZX47%KMVBI2C))*1)).TU#7:
MME[KV7W2&"4K`44Q@93B!ATQ%4._\)P_6#U2ZC=7/4%T4ZR=5,=ZBU^.8)AF
M8LEMCN)U.)/3MAE2U!6QPFJ9B@85,;,!H;<GW/;1*4A216,/TV;[W5W=O6UP
MLK)3(DD[#CMZB/918?Q;_4_ZBNJ/XJ$_ITZ$==,T9&P3#ZG*.1:'!L`QFLH*
M48OB;QS5LK1TCJ&D1JP!B=1MMX<49;:H%MK4*#/:WO=F%SO8+*U=4E(*40"1
MB8Z#TG'RJ\[\;K,6?.AGX8U?-TZZA8UE;-.5L5R3AD6=:#$*FEQ6:..KCI96
M>IB82$S!;OKK?7A1E*0M_'KJ<^W&[N,OW7EI9"TE`D$@GAMVXT"__"<GJKU0
MZL^F;KGC'5/J+C74C%L-SR*;#L3QO$:G$IZ>G_D=')Y4;U+,53<Q-AXGBC/F
M4H<``X41?35G5U?94\M]960Y`DDQX1TU5]^/CZZNO^8/5S_LB])L^XQDO(73
MNDP>#$<#P&NGP^HS!F+'8XZA?F9:9D=EB65(HTW;02S'4\79-9MAK6K;47_4
M!O\`9DO.!E]LLI0@`0"1*B`<8Z)``_&@^];_`*2?Q._1]Z"*K+_7/KKAW6ST
MW9ZKLM39TRI55M;B.,9*QI*M*BCCIJC%5$C1O*?*F\IV6_[MO>XY8W-NX_*1
M!HM[0=TMZ,HW<*+EX.VZRG4"22A4R(GV&,.KC5H/_"8C_JUCU`_^#Z/_`"RT
MW"_>'^ZCRJ4/I8_Y8[W^V#_?11#OQ4OQ!?6CZCO61BGHS]*.)YDR'D++6/T^
M3\)AP%*S"ZS-68YI$IYY:K$452E*DK[$4,J!5+M?P59;9-(;UKVT".UGM"SS
M,<X_EUAJ2V%:!ID%2I@DG;$[.`&)HEGJF]//XH/X5U1TQZIYQ]1^+4@SY5/#
M@V8L`SAC&*P08K2Q"K>DKH,255>ZDD'8R.`1Q9:NVUS*0*`V]^0[U[I]W<./
M&%<4K)@C@9_4&MRK\,CU9XUZU?1GTHZZYKHHJ'/&)1U>&9\CIXQ%328OA%2U
M'/-"@)VI-M$@7L-UAH.!6_MNZ=*1LK-'LQWM7G>3-W2Q"S(5T2,)]=M'ZXCJ
M0*]SU>KW/5ZJZ_6MZRNC/1?.W0WT[8W@N/\`4SK+UZQNDILI=-,H2R_SJCH-
M[)+B]4*:6%DHX#JP+#<`UOLD@$=HG9A:[U94JU?4M`!U)*7'&SK`.F5-J2K3
M)\0!V=<4$\Z[1;?)KQID)+CSI`"4@$@':J#SMX`T'F,9'Z[='^HC9SR'TWEH
MS&CQXA/A]558W18G$[[F,HJ&,X+V!(.H.HYQ$WC[+NU;LZWQ_G.1Y4IO2"%E
MI;ETT^"<2K62Z-4208(,$8U/K5[8W=OW;JY\P$D?*@FZ_=3\W=3L7R[5YPR6
M^2\0P>EE@CI62IC\\/*'+A:E00`=/'F.?U@=N>\._&86KN;V!L'F&U)"2%C5
M*I)`6`<#AQ\Z-\@RQJV0H-JU`GJ^53.@'5;.G3&7-0R5D9LZ5N/)2K,%CJI1
M3&$R;25IE).[>>Y';AI]'O;]O-N.J\&39>;]VX#8,!Q6C251(0"3.KB1LIO>
M#*V;G3WB]($]'SH4LK=.^N'5/J'49WSYT[EJ*JM\L4V*XA6U>"4^&1H;*:=*
M-EF)0?9`^DG6_,@-PNQ[M2W\WP7G6>Y8I2W-.EQYQRV0R`<.[#9#A*1]H''$
MF3-%=UF%E:V_=M+P'``*GSG"K+,HY5P_)N!TV!89)/+3P%W:2IJ:BKE:20[F
M/F53NY%^P)T'.V?9[N'9[MY6FRMBLH2296M;BB3B?$LJ5$[`3@*CB[NE/+U'
MX1\*4W!O2:O<]7J^?%ZM?^S[F9?_``M>4_\`I+AG!Q;?\1#R^5<Z=\?^H@*_
MVY/Q36QC_P`*.54_ATU#$79,[Y5VGV7FF'`_D?\`=ZR8^I$?\NV?\<?.@W_X
M3-,?]B;JP"?=7J3B=AX"^`83Q[>$_MAY?,T2?2R?^$3O^VG_`'Q-7Y9XRUT[
MZ@TJ9/SE#0XL]8':BP^26-:M6"W+P;6$BD#6Z_7R`^T_<K<[>Y@91G"67BN2
ME!4D.`@8J;@ZP1TI]:RILKBX8/>-R(]GK59_J`]+-;TKH)LX96Q"3&\FQ2(*
MR&:WSF'F1]J,S)8/'<@;K`CQ]O.'_P!7GT%W6X-LK.<I=4_ER5#4%?W1J3`)
M(P4B8&H`$82.-21D&]";I7=N"%^XT9ST:=6L<SOE[&LFYEK'Q+$LG"!L-Q.0
MEII:&;<JK(Q^T8V6P)U(M?F<W]6O]0^9[U9,_E&9++K]B$E"SBI32I`"CQ*"
M(!VP0#LF@UOAE*&'`X@0%<.N@1]>_P#S&F1?^]35?^51YB__`%L__3S9;_WC
MJ_Y4-'6XO]Q7Y_*C[='HTEZ2=/HI$$D<F#4*R(1<,IIU!!!]O.M?TU_]0_RO
M_O%:_P!\%`/.1-TOS-:-GIFJ8OP\?QR\3R7BU6N!9)P[-^8\O8E636BA3+.9
M:63$J*0DV&U%:'7_`%>9/W![^SGC7.S=:-V]_%-J.EO6H='A.SW%)I__``E\
MK5GK*_&.S1UVQZG:OPO*F+YPZC8H\B^8J3U5=+1X:K7T]V2J4K[-HMVY[,UA
MJU"1Y4]V/V:LZWS7=KQ"5+<]^'O4/95_W_"AS_LVCGK_`,&C*'_EU7A)DG]W
M]*R%^H[_`*=A?^.CXT6;_A,3_P!6J>H#_P`'\?\`E@HN*]X_[J/*@G]*O_+'
M>_VW_0BJ/_Q)P'_&XS>KC>IZA]/P5.H(V87IPSL?^(_3\:A+M($[]*_VQ/P3
M6S!_PH6_[-H=0/\`P9LG_P#EZCX19'_Q0*R:^HW_`*=9S_&1\:*Y_P`)B/\`
MJUCU`_\`@^C_`,LM-Q1O#_=1Y4%/I8_Y8[W^V#_?11A?Q(/QINA7HCS?7]'^
MF.1(.N7J1HO+.+X-"4I\)P"HJ5#1)7U4*/+)4N&!^7A&^Q&YE)MQ/8Y4MX2<
M$T*.TGMKR_(G3;LH#MST<$GK.TGJ'J16N3^)EU)_%$Z[=&.E_6KUO97I>E_1
M3,>/LG2'IFE%3X55+72T#SK5/1LTE6$\@D*]0P)O]GA[EJ+9#A2C$UC3VL9C
MO5?Y>BYS%(;8*CI3`'#;&W9TULE?\)X?^S:62/\`P:,V?^7$<(,[_NYK)KZ=
M?^G91_CJ^57C\*:G6O<]7J)AZ\O6AD3T+>GW,/6/-E.<?S'42)A72SI]"Q-;
MF/,E8"M)10(EW(+>](5!VH">]@5-I;%U<<*!N_6^+&26!?7BLX)3Q4K@/+B>
MJBG_`(9WHHS[D>LS3ZW?6!4?UO\`6_ZC8EJLR5%0H>/).`S`-2X#AZDD0B.(
M()MMK6V=E)91>W(/@1]HH+=F^YCS*E9C?>*\>Q,_P).Q(Z,(GHV<,;?^%U2W
M58GKS_YB_(/_`'K:K_RJ'.%?];7_`-/%EO\`M"_]_J3-Q/[BOS'PI+>CKJ9E
MG).8<Y9<K)I,4SGF>+#FRYDBA3YC$ZJ)))4><Q+_`)*GC+C?-(50>V^G!G_5
M%63RUYLZ`>[AD:H.F07,`=A(!!C:`:)>TO-V+=;31,NJF$C%1&&,<!UF!5KM
M*]1)3PO50BGJ74&:!7WA&/ANL+V]MN=H30+021CMK/SU6KW/5ZO<]7J^=;^(
M!FG%<C?C+=8\[8%EJ;.F-9/ZI8+BF%9/I]_S&*ST$6'U*4D7EJS;Y2FU;`FY
M['@\L4:K0#JKFUVB7:[??AUQ*=92ZDP.,08]:.W^,'^,3T4];7IPR7T%Z19,
MS'EK'QC])B_5>',=%%A[8/-A$<BBA3;+(99//<AV(4`+VN;`ORG*U-N:B<*'
M_;3VS6><Y8FTMT+2LJE6H#"!$""9Q/5LJZ3_`(3W=&LP=-OP\,.Q?-F%385+
MUIS)C>9<+I)T>*5\(J(:;"Z66QL0LR49D0^*L#X\)-Y4MW"U-G%)$'UV_&IN
M^G+)';'=T*6(+BRO'H@`>V)%*?/>7,[^G3K%%C$(ED_EM8]7E3&I_,DAKJ-R
M?T3.Q-SM8I(M[COSY@.UG='>GL9[2!>HU*#;I<8<5)2ZV2?"3Q.DE"Q,C'J-
M9NV#[.86>D\1!'0:$[J[ZP:CJ1D&JR9AN5/ZOOC:(F8,0DJ5G7RU=9&2%0BZ
M,5M=O#DV_41_6./;Z;I+R:ULORZK@`.K*]>`()2@:1M(VG&/;1;E.Z(MW^\4
MJ8V?K0U^B#IQC6`8/F7/>,T<F'Q9I6GI\"IY5*/+30%G:;:UB%9FLI\0+\R>
M_JN>Q3,\FRRZSR]0IH7@0AH*$$H222N#C!)`2>,$C"B;?7,D.+2TG'3M\Z"W
MU\$#.F1`38_RFI_\JCR"_P"MG_Z>;+O^\=7_`"H:,]Q?[BOS^5'ZZ-?\ZGZ=
M?]Z>@_\`*=>=:?IK/_.O\K_[Q6O]\%`3./\`BI?^,:TQ_P#A2KT/7(7JTZ6]
M=L.7Y>AZV9;-'BLRW2V+9:E6"Y86]YZ:HC_Y!YD]N\^"V4GA7/\`^J'("SFC
M=TG_`%Q./FG#W@CV4>__`(3%=##@W2#U`>HW$L/"U74+&J7+>5\2(%WP[`H?
MF*D*?\+5%0`?BO$.\+TK":D+Z6MW^ZL';I0Q60D>0Q/O(]E'._X4/,J_AH9Z
M+,%']:,H:DV_YRHXDR0_M_2AM]1H)W87_CH^-%F_X3#NC^E3U`['#6Z@"]B#
M_P`X"B]G%>\?]T'E03^E81D[W^V_Z$53-^.;D7./03\43&.KYPB2/"\[_P!5
MLX9"Q2966EKY\&CIX*B)7[$QS4NUP-0&![$<,\F6'+?34,=O-B]EN]7YJ#I5
MI6#P,``^PBCA_B<_B_=*O7SZ+,8Z.]"ND6;*O%J1L`S'UNS37T4=+@^3X,.K
M87V--')+YWG5+"&-CL!!N`3H$F79:6'M2B*&O:GVO6V\.0FWM&EE7A4LD"$P
M=F!,R<.'MHZ'_"8MB_I4]0WD.IE&?+(;W`;^24UKVXDW@_NHH9_2T#_)WNG6
M/]]%:Z72OK'@OI;_`!3L7ZO>K+(]7G>/IOU&S15]2LO/`DU<E=-55:4]=%!5
M%5E:G>2.>)6(#``@]CP^6T7+72@\*QORW.F\IWN-QF""L(<42.,R<1.!@XBC
ML?C,?BC9%_$#R-TWRST-Z98_0=%^FF/FJQ3J_CE&:):O'JF@>./#H8HFEC2T
M1:0[Y-[6%E`U*+*,O[E4J.-#OMP[4FMX+5#=JTKN4*Q6H<2-F$C9CMGJJ_'_
M`(3ONC_AI9(*.'`S3FP$@@Z_S$>SA+G7]W-9!?3K_P!.TG_'5\JO)X4U.E>Y
MZO5K[Y$RCB7XAOXMO5CJ5U"I&K?3A^&O5)ECI3E6;WJ+$>HDT:SUE?-$_NNU
M-KM-C;;'PW6KN;<`;5<\^M0%8VBMX-ZW'71-O9'2D<"OI]""?1-;!'"BI]I"
M=2.J'3GH[E'%<^]5<\87T\R7@B&3%,S8O6P4%'$JJ6L9*AE!8@:*+D^`/+H;
M4HP,:0YCF=O:-%Q]80@<28JB_K9ZALV>O#'L(S+Z;::7I#Z:\N0U%#B7K#S9
MA4JMC3&?>R9+P&K\N7$Y"`0M5,$@6]];<P#^M+L8[/;O,+7>#?*]4U96C:DI
MMFX#EPHJU0#.K3P.D>:@*)=U]_<[S@*M\D:T-J.-PX,`-G[-!^X]9PZJ-IZ!
MJ7H[THGS]@F!O#@(JXZ.6LSMF*NAJ<TYFJ]TGGUF)8A4%2[$A=M/%MAA%E11
MJ3&WT@?6%DN>YK>V9%ME&4VZ&Q:6TH;`$KUK*C!6X1IUDD^NVA\KL]1E;(4C
M6\^LDN.JE2UG#:>`Z`(`X"K4XI8IXHIX)%F@F4/#,A#*ZL+@@C0@CL>=/+>X
M;>;#B"%)4`009!!Q!!X@\#14008-9./5JO<]7J]SU>KY\GJT8K^.]F1E)5EZ
MUY3*L-"#YV&<'%M_Q%Z?*N=.^!_YV"K_`&Y'Q36ZWU&_#_\`15U<ZB1=6.I/
MIERCF_J''*LTV9JK"H3+53(^\2521[8ZEK]S,K$^/`BW>NI3I!,5G+F79]DE
MW<_F'K="G.DC;Y\#ZS1MZ*BH\-HZ3#L.I(J##Z"-(:&AAC2*&&&)0B)&D8"J
MJ@```6`XF)H7-MI2D)2(`INQW+F`9HH'PS,>#4V-X?)]JDJH8YDO:UP'!L?B
M->!G>O<S*<]M#;9BPW<,G^%Q(4/,2#!ZQC2EBX<:5J02#U4'^$]".CN!UB8A
MAG3K"X:N,WCE>G$VT^T"<N`?H'(AW?\`I1[.,KN1<6V5VZ7!B"4:H/2`LJ`]
ME+W<\O%B"LQ0LJJHJHBA44`*H%@`-``!S(%"`D0,`**J2N8<BY,S9/3U.9\K
M4&8*BD0QTT]92PU#1HQW%5,JFP)\.`/?#LJW:W@=2YF=FS<K0(27&TK(!Q@%
M0,":56]\\T(0HB>@TH:*BH\-I*:@P^F2BHJ-%CI*2)0D<<:"RJJK8``=AP89
M9E=M96Z+>W0&VFP$I2D`)2!L``P`'12=:RHR<2:##JKT'Z*==*3!Z#K-THR_
MU3H\O2R3X%38_A-%BB4<TR".1X161R;&90`2.XX9M/+1]IBB7-]W[',$A-RT
MEP)V:@#'E-*'IWTRZ=](LKTF2>EN2,*Z>9/H9)9:/+&#4-/AU#%+._F2.L-*
MJ(&=C=C;7E7'%*,DR:4Y;E=M9M!IA"6T#@D`#V"L?4?I=TXZPY7J,D]5<BX5
MU%R?5RPSU.6,9H:?$:&2:G?S(G:&J5T+(VJFVAYYMQ2#*3!K69Y3:WK7=7"$
MN(/!0!&'4:;.EG1/I!T/PG$<!Z.=,L#Z7X)B]1\WBF$X%AE)AE/457EK%YLB
M4B(K/M4+N(O8<VZ\M9E1FFLIR*RL$%%LVEM),D)``GIPICZX^G'H3ZE<M4^4
M.O/2G!>JF7J*4S8?0XO1QU#4LQL"]/*-LL+$``F-A<:'EF7UMF4F*9SW=NPS
M-KN[IM+B1TC9Y':/2DID_P!&WI3R#TOQGHME'T^Y4P?I7F1HFS+DA<&I):+$
MW@E$T;5JSHYJ&1@"IE+$>'-KNG%*U$F:26>YF4V]J;9MA`:5M3I$'SZ?6A&Z
M6=$^D'0_"<1P'HYTRP/I?@N+U'S>*X5@6&4F&4]15;!%YLB4B(&?:H&XB]N4
M<>6LRHS1CE.165@@HMFTMI)DA(`$^E`MUL]!/HV]1F:H,\];/3GECJ#G&!$C
M;,]70^7731QZ(L\U*T33!1HOF%K#0:<=:O'6Q"3`HDSS<#)<R=[VY80M?21C
MZD1/K2UK/27Z8,0Z=8)TBKO3[D^LZ7Y;J5K,"R#)E[#'PJEK5C,(J$IVA*"8
MJ2#);<?$\J+ES5JDS2YS=#*EVPMRPV6DF0G2(!Z8C;UT(O37I5TTZ-Y93)?2
M?(>$].,HQ3S5,>6L%H:?#J%:BH(,L@AI51`SD#<;:\;<<4LRHR:,LLRFULFN
MZMT);1MA(`'L%+_E*,**YZUNJ.>>B7I7ZU]7>F^`2YISATXP@XQAV7H$:2:K
MAHJF&:JC0(&.XTXDL0#;OQ1:-A3@!V&@MOKFC]EE3K[(E:!,>1$^Z:J>Z/\`
MXV_X1>5,"SMU4R_F>KZ79TZPUL>/]4LD-@6)R8M5X\*..C>1XZ598'F*1*A>
M-@'L"=;\7N9:^2!@8V8U%N4=LNZS*%OIU-K<.I8TJ)U1'##U&!VU'E_%D]6W
MJZ,^6/PU_0]CV,0U,GD-U_ZD1?R'*U`KC2=(/,5IB.^WS/J/;GAE[;>+BO05
M4]JF:YM*,HM5'^_7@D=>V/?/50J='?PE,?ZD9TPKKG^)SUOJ_63U4PZ8567>
ME[F2CZ;Y>DW>8JT^$H(HZ@QDZ>8@0VU5N_*.Y@`-+8@>^C3)^RERX?%SG#IN
M71L3L;3Z83[`#Q!JUS'NA'27,]32U..Y*IJ]J"".FPV$O.D%+31*$2*"&*18
MXD4#144#F.>_?TR[C[SWYO<ULQ<OJPU+6X8`X`:X2.H`5/5EFUQ;-AMHZ4C8
M``/E3"_IAZ#2*5?IM1,#X;ZG_J;P&?\`0D/97_SBVO\`3.?X=*_[27W],^ZA
MOH*&DPRAHL-H(134.'Q1P4=.M]L<42"-%%[FP``YDYE65V]C:MVS"0AII(2E
M(V!*1`'H!%$RUE2B3M-2^+ZI7N>KU>YZO42;,WX<?HASCUBJ/4!F;TZX%C'6
M2JQ:FQVHS]*:[YU\7HS&8:D[:@)O0Q+;W;:=N*A>.A.F<*!=SV=Y*]=_FELI
M+Q,ZL9D<=M'9XEH:5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU1JW_`'CJ_P#)?Y*3_+?Y'[)_
MRG^K[?AS8JCGVFM?')7\L_VC<2\O_86^=_FE5YG\L_F_];K^:;W\W_1_F/\`
M'MTW<.E3W?\`'\JQYL]'\Q/_`"SIU'9JU_A-7^Y=_P"2)AO^\7^3'_)._P!X
MNY_R/^KPF5MK(&U_N8V>FSTIZY6E%>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZ
MO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[G
6J]7N>KU>YZO5[GJ]7N>KU>YZO5__V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
